Schering appoints WS to Asoprisnil brief
Pharma giant Schering is to launch an international PR and medical education push for Asoprisnil, its non-surgical female genital tumour treatment currently in phase III trials.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>